Aberrant activation of NF-κB/Rel and AP-1 in adult T-cell leukemia

被引:0
|
作者
Mori, N [1 ]
Fujii, M [1 ]
机构
[1] Univ Ryukyus, Fac Med, Dept Virol, Nishihara, Okinawa 9030215, Japan
来源
TWO DECADES OF ADULT T-CELL LEUKEMIA AND HTLV-I RESEARCH | 2003年 / 50期
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adult T-cell leukemia (ATL) is a fatal T-lymphoproliferative disorder, and its development is associated with infection by human T-cell leukemia virus type I (HTLV-I). Several studies have suggested that aberrant transcription of cellular genes in HTLV-I infected cells plays a key role in the development of the disease. For instance, two transcription factors, nuclear factor kappa B (NF-kappaB)/Rel and activating protein-1 (AP-1), are transiently activated in normal T cells by growth-signals, whereas they are constitutively activated in HTLV-I infected T cells in vitro as well as in vivo. The HTLV-I oncoprotein Tax is responsible for the activation of NF-kappaB/Rel and AP-1 in HTLV-T transformed T-cell lines, and it induces a variety of cellular genes through NF-kappaB/Rel and AP-1. Unlike HTLV-I transformed T-cell lines, leukemic cells of ATL patients express extremely low levels of Tax protein, but NF-kappaB/Rel and AP-1 in leukemic cells are constitutively activated. Thus, the aberrant activation of NF-kappaB/Rel and AP-1 may be a key factor underlying the prolonged survival and proliferation of HTLV-I infected T cells both at the initial and late stages of leukemogenesis, although the mechanisms are different. In this review, we discuss the involvement of NF-kappaB/Rel and AP-1 in Tax-dependent and independent steps of leukemogenesis, and their role as potential therapeutic targets for treatment of ATL.
引用
收藏
页码:73 / 92
页数:20
相关论文
共 50 条
  • [1] Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma
    Ishikawa, Chie
    Senba, Masachika
    Mori, Naoki
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (02) : 633 - 643
  • [2] Injury induces alterations in T-cell NFκB and AP-1 activation
    O'Suilleabhain, CB
    Kim, SM
    Rodrick, MR
    Mannick, JA
    Lederer, JA
    SHOCK, 2001, 15 (06): : 432 - 437
  • [3] Pseudoephedrine inhibits T-cell activation by targeting NF-κB, NFAT and AP-1 signaling pathways
    Fiebich, Bernd L.
    Collado, Juan A.
    Stratz, Cristian
    Valina, Christian
    Hochholzer, Willibald
    Munoz, Eduardo
    Bellido, Luz M.
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2012, 34 (01) : 98 - 106
  • [4] Constitutive activation of NF-κB in primary adult T-cell leukemia cells
    Mori, N
    Fujii, M
    Ikeda, S
    Yamada, Y
    Tomonaga, M
    Ballard, DW
    Yamamoto, N
    BLOOD, 1999, 93 (07) : 2360 - 2368
  • [5] Activation of transcription factors AP-1 and Rel/NF-κB and regulation of gene expression by acetaldehyde
    Román, J
    Parés, A
    Gassó, M
    Giménez, A
    Rubio, M
    Caballería, J
    Rodés, J
    Fernández-Checa, JC
    HEPATOLOGY, 1998, 28 (04) : 237A - 237A
  • [6] AP-1 and NF-κB synergize to transcriptionally activate latent HIV upon T-cell receptor activation
    Hokello, Joseph
    Lakhikumar Sharma, Adhikarimayum
    Tyagi, Mudit
    FEBS LETTERS, 2021, 595 (05) : 577 - 594
  • [7] Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells
    Mori, N
    Fujii, M
    Iwai, K
    Ikeda, S
    Yamasaki, Y
    Hata, T
    Yamada, Y
    Tanaka, Y
    Tomonaga, M
    Yamamoto, N
    BLOOD, 2000, 95 (12) : 3915 - 3921
  • [8] Constitutive activation of NF-κ B in primary adult T-cell leukemia cells.
    Mori, N
    Fujii, M
    Ikeda, S
    Yamada, Y
    Tomonaga, M
    Ballard, DW
    Yamamoto, N
    BLOOD, 1998, 92 (10) : 82A - 82A
  • [9] Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-κB oncogenesis
    A S Liss
    R Tiwari
    J Kralova
    H R Bose
    Oncogene, 2010, 29 : 4925 - 4937
  • [10] Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-κB oncogenesis
    Liss, A. S.
    Tiwari, R.
    Kralova, J.
    Bose, H. R., Jr.
    ONCOGENE, 2010, 29 (35) : 4925 - 4937